Are they serious going into a Phase 2 trial with this data?
I suppose I'm just ready for Abbott to scoop this up and to count all the cash on the balance sheet. CNS is always full of disasters. At least, TD is a novel indication and under served.
I think everyone was expecting really good data because small trials are easy to control. My disappointment is really that it wasn't well done. In a larger trial this would cost a fortune so I just hope they work out the issues.